Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFINE - Evaluating therapies for COVID-19
ISRCTN14212905Phase 2Completed
- Sponsor
- University of Edinburgh
- Start
- Jul 2020
- Modality
- Small Molecules, Cell Therapies
01
Overview
Phase 2, randomised, open-label trial of Nafabelltan, GB0139 and SARS-CoV-2 virus-specific T-cells in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by University of Edinburgh. Primary endpoints: Safety of candidate agents as add-on therapy to standard of care and Safety of SARS-CoV-2 virus-specific T-cells as add-on therapy to standard of care. Started Jul 2020; status: completed.
02
Drugs
NafabelltanGB0139SARS-CoV-2 virus-specific T-cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN14212905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14212905.